An Ebola Vaccine In The Making
On July 31, 2015, The Lancet journal published the first results of the phase 3 cluster randomized trial of a novel Ebola virus vaccine1,2. The study that was sponsored and led by World Health Organization (WHO) showed very promising results. It involved the cooperation of researchers, health workers, and community facilitators in Guinea to enable the study of 7651 people in the trial to test the efficacy of a recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Ebola (Zaire). The investigators (Ana Maria Henao-Restrepo et al) concluded that their interim analysis indicated that the vaccine “might be highly efficacious and safe”. The vaccination trial technique used in the trial was “ring vaccination”1,2. This method involves identifying a newly diagnosed person with Ebola, and then tracking down their contacts and contacts of contacts. Over 90% of the study’s staff were from Guinea. The vaccine is not yet licensed. The whole world awaits with bated breath more hopefully successful and encouraging news regarding development of a fully functional Ebola Vaccine.

Ebola Virus under the microscope (http://www.md-health.com/Ebola-Virus-Disease-Pictures.html)
REFERENCES
1. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. The Lancet. Published online July 31, 2015.
2. An Ebola vaccine: first results and promising opportunities. Editorial. The Lancet. Published online July 31, 2015.
Macaulay Onuigbo MD MSc FWACP FASN MBA (Chief Medical Editor, BHO)
Last updated August 12, 2015.
